Your browser doesn't support javascript.
loading
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Woelber, Linn; Bommert, Mareike; Prieske, Katharina; Fischer, Inger; Zu Eulenburg, Christine; Vettorazzi, Eik; Harter, Philipp; Jueckstock, Julia; Hilpert, Felix; de Gregorio, Niko; Iborra, Severine; Sehouli, Jalid; Ignatov, Atanas; Hillemanns, Peter; Fuerst, Sophie; Strauss, Hans-Georg; Baumann, Klaus; Beckmann, Matthias; Mustea, Alexander; Meier, Werner; Wimberger, Pauline; Hanker, Lars; Canzler, Ulrich; Fehm, Tanja; Luyten, Alexander; Hellriegel, Martin; Kosse, Jens; Heiss, Christoph; Hantschmann, Peer; Mallmann, Peter; Tanner, Berno; Pfisterer, Jacobus; Mahner, Sven; Schmalfeldt, Barbara; Jaeger, Anna.
Afiliação
  • Woelber L; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bommert M; Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany.
  • Prieske K; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Fischer I; Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Zu Eulenburg C; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Vettorazzi E; Department of Epidemiology, UMCG, Universität Groningen, Groningen, Netherlands.
  • Harter P; Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Jueckstock J; Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany.
  • Hilpert F; Department of Gynecology and Obstetrics, University Hospital, LMU-University of Munich, Munich, Germany.
  • de Gregorio N; Oncologic Medical Center at the Jerusalem Hospital Hamburg, Hamburg, Germany.
  • Iborra S; Department of Obstetrics and Gynecology, University of Ulm Medical Center, Ulm, Germany.
  • Sehouli J; Gynecology and Gynecologic Oncology, Uniklinik RWTH Aachen, Aachen, Germany.
  • Ignatov A; Department of Gynecology, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany.
  • Hillemanns P; Department of Obstetrics and Gynecology, University Hospital Magdeburg, Magdeburg, Germany.
  • Fuerst S; Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.
  • Strauss HG; Department of Gynecology and Obstetrics, University Hospital, LMU-University of Munich, Munich, Germany.
  • Baumann K; Department of Gynecology, University Hospital Halle, Halle, Germany.
  • Beckmann M; Department of Gynecology, Medical Center Ludwigshafen, Ludwigshafen, Germany.
  • Mustea A; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Meier W; Department of Gynecology and Gynecologic Oncology, University Medical Center Bonn, Bonn, Germany.
  • Wimberger P; Department of Obstetrics and Gynecology, Evangelical Hospital Düsseldorf, Düsseldorf, Germany.
  • Hanker L; Department of Gynecology and Obstetrics, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Canzler U; Department of Gynecology and Gynecologic Oncology, University Medical Center Lübeck, Lübeck, Germany.
  • Fehm T; Department of Gynecology and Obstetrics, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Luyten A; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
  • Hellriegel M; Department of Gynecology and Obstetrics, Medical Center Wolfsburg, Wolfsburg, Germany.
  • Kosse J; Department of Gynecology and Gynecologic Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Heiss C; Department of Gynecology and Obstetrics, Sana Klinikum Offenbach, Offenbach, Germany.
  • Hantschmann P; Department of Gynecology, Medical Center am Eichert, Alb Fils Clinic, Klinik am Eichert, Göppingen, Germany.
  • Mallmann P; Department of Gynecology and Obstetrics, Medical Center Altötting, Altötting, Germany.
  • Tanner B; Department of Gynecology and Gynecologic Oncology, University Medical Center Köln, Köln, Germany.
  • Pfisterer J; Department of Gynecology and Obstetrics, Medical Center Oranienburg, Oranienburg, Germany.
  • Mahner S; Gynecologic Oncology Center Kiel, Kiel, Germany.
  • Schmalfeldt B; Department of Gynecology and Obstetrics, University Hospital, LMU-University of Munich, Munich, Germany.
  • Jaeger A; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Geburtshilfe Frauenheilkd ; 80(12): 1221-1228, 2020 Dec.
Article em En | MEDLINE | ID: mdl-33293730
ABSTRACT
Since the publication of the updated German guideline in 2015, the recommendations for performing pelvic lymphadenectomy (LAE) in patients with vulvar cancer (VSCC) have changed considerably. The guideline recommends surgical lymph node staging in all patients with a higher risk of pelvic lymph node involvement. However, the current data do not allow the population at risk to be clearly defined, therefore, the indication for pelvic lymphadenectomy is still not clear. There are currently two published German patient populations who had pelvic LAE which can be used to investigate both the prognostic effect of histologically verified pelvic lymph node metastasis and the relation between inguinal and pelvic lymph node involvement. A total of 1618 patients with primary FIGO stage ≥ IB VSCC were included in the multicenter AGO CaRE-1 study (1998 - 2008), 70 of whom underwent pelvic LAE. During a retrospective single-center evaluation carried out at the University Medical Center Hamburg-Eppendorf (UKE), a total of 514 patients with primary VSCC treated between 1996 - 2018 were evaluated, 21 of whom underwent pelvic LAE. In both cohorts, around 80% of the patients who underwent pelvic LAE were inguinally node-positive, with a median number of three affected groin lymph nodes. There were no cases of pelvic lymph node metastasis without inguinal lymph node metastasis in either of the two cohorts. Between 33 - 35% of the inguinal node-positive patients also had pelvic lymph node metastasis; the median number of affected groin lymph nodes in these patients was high (> 4), and the maximum median diameter of the largest inguinal metastasis was > 40 mm in both cohorts. Pelvic lymph node staging and pelvic radiotherapy is therefore probably not necessary for the majority of node-positive patients with VSCC, as the relevant risk of pelvic lymph node involvement was primarily found in node-positive patients with high-grade disease. More, ideally prospective data collections are necessary to validate the relation between inguinal and pelvic lymph node involvement.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2020 Tipo de documento: Article